Jim Cramer: Merck is a buy after the drugmaker’s post-earnings dip — here’s why
Jim Cramer’s daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Merck : The drugmaker reported a better-than-expected quarter. It raised its…
Read more Jim Cramer: Merck is a buy after the drugmaker’s post-earnings dip — here’s why